Febrile seizure recurrence reduced by intermittent oral levetiracetam

Lin-Yan Hu1, Li-Ping Zou1, Jian-Min Zhong2

  • 1Department of Pediatrics, Chinese PLA General Hospital Beijing, 100583, China ; Department of Pediatrics, Chinese PLA General Hospital Beijing, 100583, China.

Insights

Levetiracetam (LEV) effectively prevents febrile seizure (FS) recurrence in children. This treatment is also more cost-effective and has minimal side effects compared to standard care.

Area of Science:

  • Pediatric Neurology
  • Clinical Pharmacology

Background:

  • Febrile seizures (FS) are the most common childhood seizure disorder and a frequent reason for pediatric emergency admissions.
  • Identifying effective and safe therapies to prevent FS recurrence is a significant clinical challenge.

Purpose of the Study:

  • To evaluate the efficacy and safety of intermittent oral levetiracetam (LEV) for preventing febrile seizure recurrence in children.
  • To assess the cost-effectiveness of LEV compared to a control group.

Main Methods:

  • A randomized controlled trial involving 115 children with a history of two or more FS.
  • Participants were assigned to receive either levetiracetam (LEV) or a control (2:1 ratio).
  • LEV was administered orally at 15-30 mg/kg/day for one week at fever onset, followed by a gradual taper.

Main Results:

  • The LEV group showed a significantly lower FS recurrence rate (11/78 children) compared to the control group (19/37 children).
  • LEV treatment was associated with a lower FS recurrence per fever episode.
  • The cost of preventing FS recurrence with LEV was lower than the control group.
  • The primary side effect observed was mild drowsiness in one patient.

Conclusions:

  • Intermittent oral levetiracetam is an effective strategy for preventing febrile seizure recurrence in children.
  • LEV therapy offers a cost-effective solution, reducing medical resource expenditure.
  • The treatment demonstrates a favorable safety profile with minimal adverse effects.
Abstract

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Seizures l: Introduction01:20

Seizures l: Introduction

Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
13
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.4K
Seizures ll: Types01:19

Seizures ll: Types

Seizures are sudden bursts of abnormal electrical discharge in the brain that interfere with normal function. They are commonly divided into three groups: focal seizures, generalized seizures, and other types that do not fit neatly into either category.Focal SeizuresFocal seizures begin in a single brain region. When awareness is preserved, they are called focal aware seizures and may cause sensations such as tingling, unusual smells, or flashing lights. When awareness is impaired, they are...
21